---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-047511"
form_type: "8-K"
ticker: "PACB"
cik: "0001299130"
company_name: "PACIFIC BIOSCIENCES OF CALIFORNIA, INC."
filed_at: "2024-04-16T23:59:59+00:00"
generated_at: "2026-06-03T22:04:28.705626+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PacBio reports preliminary Q1 rev $38.8M (flat YoY), slashes FY2024 guidance to $170-200M, cuts costs $50-75M

## Summary
- Preliminary Q1 2024 revenue $38.8M, roughly flat vs $38.9M in prior-year period.
- Revio shipments 28 systems in Q1; installed base reached 201 as of March 31, 2024.
- FY2024 revenue guidance reduced to $170-200M; long-term $500M 2026 goal unlikely.
- Plan to reduce annualized non-GAAP operating expense run rate by $50M-$75M by end of 2024.
- Cash, cash equivalents & investments expected to be $435-450M by year-end, down from $562M at Q1 end.

## SEC filing metadata
- accession: 0001104659-24-047511
- form_type: 8-K
- ticker: PACB
- cik: 0001299130
- company_name: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
- filed_at: 2024-04-16T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1299130/000110465924047511/0001104659-24-047511-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1299130/000110465924047511/tm2411926d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-047511
- JSON: https://secwatch.observer/filing/0001104659-24-047511.json
- Plain text: https://secwatch.observer/filing/0001104659-24-047511.txt

## Key facts
- Earnings Releases
  PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported the quarter ended March 31, 2024 results: revenue $38.8 million. Guidance lowered.
  - Period: the quarter ended March 31, 2024
  - Revenue: $38.8 million
  - Guidance: lowered
  - Result: preliminary results
  source text: – PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2024. Preliminary First Quarter Results · Preliminary revenue of $38.8 million, roughly flat compared with $38.9 million in the prior-year period. · Instrument revenue of $19.0 million compared with $20.7 million in the prior-year period. · Consumables
  evidence_url: https://www.sec.gov/Archives/edgar/data/1299130/000110465924047511/0001104659-24-047511-index.htm
- Earnings Releases
  PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported 2024 results: revenue $170 million to $200 million. Guidance lowered.
  - Period: 2024
  - Revenue: $170 million to $200 million
  - Guidance: lowered
  - Result: guidance update
  source text: PacBio now expects 2024 revenue to be in the range of $170 million to $200 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1299130/000110465924047511/0001104659-24-047511-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.